Clinical Data Inc

Clinical Data — BMO Capital Markets Focus on Healthcare Conference 2009

30 slides from Clinical Data's conference presentation, Aug 5, 2009

  1. Slide 1: BMO Capital Markets Focus on Healthcare Conference

    Slide 1: BMO Capital Markets Focus on Healthcare Conference

    1 BMO Capital Markets Focus on Healthcare Conference August 5, 2009

  2. Slide 2: Forward-Looking Statement

    Slide 2: Forward-Looking Statement

    Forward-Looking Statement 2 This presentation contains certain forward-looking information about Clinical Data that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements a

  3. Slide 3: Investment Opportunity

    Slide 3: Investment Opportunity

    Investment Opportunity Clinical Data is a biotechnology company developing late-stage drugs that are first-in-class, best-in-category, or both 3 Central Nervous System Cardiovascular Disease Oncology

  4. Slide 4: Current Value Drivers

    Slide 4: Current Value Drivers

    Current Value Drivers Two Phase III drugs: Vilazodone(tm): first-in-class dual acting serotonergic antidepressant Stedivaze(tm): potential best-in-class drug used as a vasodilator for cardiac stress testing Deep pipeline of drugs and biomarkers candidates Genetic testing business for inherited cardi

  5. Slide 5: Vilazodone: New Options Needed in the Treatment of Depression

    Slide 5: Vilazodone: New Options Needed in the Treatment of Depression

    Vilazodone: New Options Needed in the Treatment of Depression Common chronic condition affects approximately 18M U.S. Leading cause of disability in U.S. for ages 15-44 Majority of patients do not achieve success with 1st therapy Side effects are common Certain side effects influence prescribing mor

  6. Slide 6: Vilazodone for Treatment of Depression

    Slide 6: Vilazodone for Treatment of Depression

    Vilazodone for Treatment of Depression First-in-class antidepressant with a dual serotonergic mechanism of action SSRI 5HT1A Demonstrated superiority to placebo in 2 Phase III trials Well-tolerated with low discontinuation rate Sexual function is similar to placebo as measured by validated scales Op

  7. Slide 7: Summary of Development Program

    Slide 7: Summary of Development Program

    Summary of Development Program 2/2 positive Phase III pivotal* trials Industry average for depression trials is ~50% Efficacy claim will be based on pivotal trials at 40mg QD Total database of >2,200 patients including long-term exposure Completed studies required for NDA submission including ECG ef

  8. Slide 8: Summary of Phase III Pivotal Trials

    Slide 8: Summary of Phase III Pivotal Trials

    Summary of Phase III Pivotal Trials Patients 18-70 years of age with moderate to severe depression Primary endpoint change from baseline to week 8 in MADRS score, ITT/LOCF Baseline MADRS score of 31 Secondary endpoints HAMD, HAMA Day 0 10 mg Week 1 20 mg Week 2 40 mg Week 8 8

  9. Slide 9: Low Discontinuation Rates in Phase III Studies

    Slide 9: Low Discontinuation Rates in Phase III Studies

    Low Discontinuation Rates in Phase III Studies 9 1st Phase III Trial 1st Phase III Trial 2nd Phase III Trial 2nd Phase III Trial Vilazodone Placebo Vilazodone Placebo Enrolled 205 205 240 241 Discontinued 53 (25.9%) 51 (24.9%) 47 (19.6%) 46 (19.1%) Adverse Event 19 (9.3%) 10 (4.9%) 12 (5.1%) 4 (1.7%

  10. Slide 10: 2nd Phase III Trial Confirms Superiority to Placebo

    Slide 10: 2nd Phase III Trial Confirms Superiority to Placebo

    2nd Phase III Trial Confirms Superiority to Placebo 10 Least Squares Mean Change at Week 8 Least Squares Mean Change at Week 8 LS Mean Treatment Difference p-value 1st Phase III Vilazodone N = 198 Placebo N = 199 MADRS -12.9 -9.6 -3.2 0.001 HAMD17 -10.4 -8.6 -1.7 0.022 HAMA -6.5 -5.2 -1.4 0.031 2nd

  11. Slide 11: Adverse event comparison with marketed antidepressants

    Slide 11: Adverse event comparison with marketed antidepressants

    Zoloft(r) (sertraline hydrochloride)* Zoloft(r) (sertraline hydrochloride)* Zoloft(r) (sertraline hydrochloride)* AE Drug Placebo Nausea 26% 12% Diarrhea/ loose stools 18% 9% Somnolence 13% 6% Tremor 11% 3% Sweating Increased 8% 3% Ejaculation failure 7% <1% Dyspepsia 6% 3% Vilazodone Phase III Tria

  12. Slide 12: Sexual Dysfunction is Common in Depression

    Slide 12: Sexual Dysfunction is Common in Depression

    Sexual Dysfunction is Common in Depression 40 to 50% of depressed patients report sexual dysfunction1 Drug-induced SD is common with antidepressants SSRI use results in 25-80% incidence of drug-induced sexual dysfunction2 Up to 90% of patients who experience antidepressant-induced sexual dysfunction

  13. Slide 13: Vilazodone Impact on Overall Sexual Function Comparable to Placebo

    Slide 13: Vilazodone Impact on Overall Sexual Function Comparable to Placebo

    Vilazodone Impact on Overall Sexual Function Comparable to Placebo 13 Change from Baseline in CSFQ Total Score Change from Baseline in CSFQ Total Score Change from Baseline in CSFQ Total Score Change from Baseline in CSFQ Total Score Change from Baseline in CSFQ Total Score Change from Baseline in C

  14. Slide 14: Long Term Exposure Study Complete for NDA Submission

    Slide 14: Long Term Exposure Study Complete for NDA Submission

    Long Term Exposure Study Complete for NDA Submission 1 year, open label treatment study Regulatory minimum requirement is 300 patients on drug for 6 months and 100 patients for 12 months 2 week titration to 40 mg QD Baseline HAMD17 ^ 18 Results were consistent with pivotal trials which demonstrated

  15. Slide 15: Regulatory Approval of Antidepressants

    Slide 15: Regulatory Approval of Antidepressants

    Regulatory Approval of Antidepressants FDA requires demonstration of: Acceptable risk/benefit ratio Statistical significance in two adequately powered controlled trials Robust results on multiple measures using multiple analytic methods (MADRS, HAMD, CGI) Safety in both acute and chronic administrat

  16. Slide 16: Commercial Opportunity for Vilazodone in the Treatment of Depression

    Slide 16: Commercial Opportunity for Vilazodone in the Treatment of Depression

    Commercial Opportunity for Vilazodone in the Treatment of Depression 16

  17. Slide 17: Depression is Largest Segment of CNS Market

    Slide 17: Depression is Largest Segment of CNS Market

    Depression is Largest Segment of CNS Market U.S. market continues to grow1 $12B annual sales 208M+ prescriptions Medical cost to treat depression is close to $30B annually2 Vilazodone relevant market SSRIs (i.e. Zoloft(r), Lexapro(r), Celexa(r), Prozac(r)) SNRIs (i.e. Cymbalta(r), Effexor(r)XR, Pris

  18. Slide 18: Prescriptions Increasing at 4% CAGR

    Slide 18: Prescriptions Increasing at 4% CAGR

    Prescriptions Increasing at 4% CAGR* 18 * IMS Health's National Prescription Audit Year Includes SSRIs, SNRIs, and Wellbutrin

  19. Slide 19: Depression Market is Highly Concentrated to Top Prescribers

    Slide 19: Depression Market is Highly Concentrated to Top Prescribers

    Market Decile Number of Prescribers Minimum TRx Maximum TRx Average TRx Cum. % of Prescribers Cum. % of TRx 10 3,517 3,545 28,320 5,123 0.5% 10.0% 9 6,437 2,342 3,545 2,800 1.5% 20.0% 8 8,890 1,792 2,341 2,027 2.9% 30.0% 7 11,245 1,445 1,792 1,603 4.7% 40.0% 6 13,864 1,174 1,445 1,300 6.8% 50.0% 5 1

  20. Slide 20: Primary Market Research Confirms Opportunity

    Slide 20: Primary Market Research Confirms Opportunity

    Primary Market Research Confirms Opportunity Quantitative, primary market research with PCPs & Psychiatrists 50% of time physicians do not achieve desired results with first therapy Tolerability is often the reason for patient discontinuations 60% of physicians felt lack of sexual dysfunction was ex

  21. Slide 21: Depression Drugs Compete in Generic Market

    Slide 21: Depression Drugs Compete in Generic Market

    Depression Drugs Compete in Generic Market 21 Quarterly Sales 2003 - 2008 IMS HEALTH'S National Sales Perspective Celexa(r) goes generic (Q4'04) Zoloft(r) goes generic (Q3'06)

  22. Slide 22: Market Share Driven By Many Factors

    Slide 22: Market Share Driven By Many Factors

    Market Share Driven By Many Factors* 22 * N Engl J Med 2008;358:252-60. Based on FDA threshold for measuring effect size ** Clinical Data Inc. Phase III Registration Trial Results ^ 2008 IMS HEALTH'S National Sales Perspective Vilazodone has not been approved by FDA. Clinical Data is making no claim

  23. Slide 23: Vilazodone Addresses Unsatisfied Market

    Slide 23: Vilazodone Addresses Unsatisfied Market

    Vilazodone Addresses Unsatisfied Market Physicians/patients continue to seek new options Vilazodone's unique mode of action and safety/tolerability profile provide significant differentiation Favorable physician acceptance in market research1 Received a 7/10 rating Over 60% would probably or definit

  24. Slide 24: Stedivaze: Vasodilator for Cardiac Stress Testing

    Slide 24: Stedivaze: Vasodilator for Cardiac Stress Testing

    Stedivaze: Vasodilator for Cardiac Stress Testing Stedivaze: Vasodilator for Cardiac Stress Testing 24 1 AMR Monthly Monitor

  25. Slide 25: Stedivaze Clinical Development Program

    Slide 25: Stedivaze Clinical Development Program

    Stedivaze Clinical Development Program Decision to pause the start of Phase III trials Insights gained from July 28, 2009 FDA Advisory Board meeting Revising trial protocol to reflect recent feedback Initiated Phase I studies in chronic obstructive pulmonary disease and asthma to demonstrate safety

  26. Slide 26: Therapeutics Pipeline

    Slide 26: Therapeutics Pipeline

    Therapeutics Pipeline Current Stage Lead Discovery Preclinical Phase I Phase II Phase III NDA Marketed Novartis Confidential Partner Vilazodone(tm) Major Depression Stedivaze(tm) Cardiac Imaging ATL1222: Acute Inflammation ATL844: Diabetes / Asthma ATL313 : Ophthalmic Pain AVN316: Oncology Projected

  27. Slide 27: Dx for Inherited Cardiac Conditions: FAMILION

    Slide 27: Dx for Inherited Cardiac Conditions: FAMILION

    Dx for Inherited Cardiac Conditions: FAMILION(r) Over 100% Growth Year Over Year* *Calendar Year 0 ..5 1 1.5 2 2.5 2004 2005 2006 2007 2008 New Sales Force $ (Millions) $3 2009 27

  28. Slide 28: Clinical Data (CLDA) Profile

    Slide 28: Clinical Data (CLDA) Profile

    Clinical Data (CLDA) Profile* 28 Revenue: $ 3.2M (3 mo.) $10.4M (Year end) Cash & Marketable Securities: $56.4M $15.6M Sale of Cogenics business (4/15) Debt: $53.2M** Shares Outstanding: 23.7M Insider Ownership: ~ 50% Substantially all shares purchased *As of 3/31/09 unless otherwise indicated **Net

  29. Slide 29: Upcoming Events in 2009

    Slide 29: Upcoming Events in 2009

    Upcoming Events in 2009 Submit vilazodone NDA to the FDA Continue preparations for commercialization Complete Phase I studies for Stedivaze in COPD and asthma; start Phase III program in 2H 2009 Establish partnerships for other preclinical programs Continue to grow genetic testing business 29

  30. Slide 30: Thank You

    Slide 30: Thank You

    os — fa 4 = u Fiom Tifgeted Science if & Ye to Beiter Healthcare™ & & , ie y | CLINICAL Thank You

Source: SEC EDGAR · 8-K filed Aug 5, 2009

More decks from Clinical Data Inc